Understanding EIB
#

Tyronib® (Imatinb Mesylate) ⇒ Contact Us

Taj Pharma is one of the largest generic pharmaceutical company in India. We hold top positions in different established markets worldwide and are building a strong presence in many emerging generics markets. You can contact Taj Pharma India's business by telephone on +91-22-2637-4592, if you have an enquiry about the company, our healthcare business, or one of our medicines.

Media professionals can contact our India Press Office team directly with enquiries. Please note that this e-mail address is intended for journalists with specific enquiries. Unfortunately we are unable to respond to any non-media enquiries submitted via this route.

Address

Taj Pharma India Brands
Taj Pharma Group (India)
P.O. Box No. 12002,
Azad Nagar Post office,
Andheri (w), Mumbai - 400 053.
India.

Phone:

+91-22-2637 4592

Fax:

+91-22-2634-1274

E-mail:

tyronib@tajpharma.com

Contact Form

Uses

Tyronib® (Imatinb Mesylate), is a targeted therapy used to treat certain types of Leukaemia and soft tissue sarcoma, it may also be used to treat other types of cancers as part of research trial.

Tyronib® (Imatinib Mesylate) may be used to treat:

  • Chronic myeloid leukaemia (CML)
  • A type of acute lymphoblastic leukaemia (ALL) called Philadelphia chromosome positive (Ph+ ALL)
  • Gastro-intestinal stromal tumours (GISTs)
  • A rare type of soft tissue cancer called dermatofibrosarcoma protuberans (DFSP)
  • Other types of cancers as part of a research trial.

Important Safety Information

  • Pregnancy Category D:Imatinib can cause fetal harm when administered to a pregnant woman. There have been post-market reports of spontaneous abortions and infant congenital anomalies from women who have taken Imatinib.

    There are no adequate and well-controlled studies with Imatinib in pregnant women. Women should be advised not to become pregnant when taking Imatinib. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

  • Nursing Mothers:Imatinib and its active metabolite are excreted into human milk. Based on data from three breastfeeding women taking Imatinib, the milk:plasma ratio is about 0.5 for imatinib and about 0.9 for the active metabolite.

  • Pediatric Use:Imatinib safety and efficacy have been demonstrated in children with newly diagnosed Ph+ chronic phase CML and Ph+ ALL. There are no data in children under 1 year of age.

  • Geriatric Use: In the CML clinical studies, approximately 20% of patients were older than 65 years. In the study of patients with newly diagnosed CML, 6% of patients were older than 65 years. No difference was observed in the safety profile in patients older than 65 years as compared to younger patients, with the exception of a higher frequency of edema. The efficacy of Imatinib was similar in older and younger patients.

Patient Information  
Full Prescribing Information